JeffreyLouisSugarmanMD
Dermatology • Santa Rosa, CADermatologic Surgery, Pediatric Dermatology
Physician
Dr. Sugarman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2725 Mendocino Ave
Santa Rosa, CA 95403Phone+1 707-545-4537Fax+1 707-545-6726
Education & Training
University of California (San Francisco)Residency, Dermatology, 1999 - 2002
University of WashingtonResidency, Pediatrics, 1996 - 1999
University of California San Diego School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1999 - 2027
UT State Medical License 2018 - 2020
WA State Medical License 1996 - 1999- American Board of Dermatology Dermatology
- American Board of Dermatology Pediatric Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2011-2013
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis Start of enrollment: 2006 Dec 01
- Systemic Therapies for Pediatric Atopic Dermatitis Start of enrollment: 2011 Oct 01
- A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Effect of Topical Microencapsulated Benzoyl Peroxide on the Skin Microbiome in Rosacea: A Randomized, Double-Blind, Crossover, Vehicle-Controlled Clinical Trial.Yvonne Nong, Jeffrey Sugarman, Jean Philippe York, Ofra Levy-Hacham, Dawnica Nadora
The Journal of Clinical and Aesthetic Dermatology. 2024-08-01 - 3 citationsBerdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials.Jeffrey L Sugarman, Adelaide Hebert, John C Browning, Amy S Paller, Stephen Stripling
Journal of the American Academy of Dermatology. 2024-02-01 - 1 citationsDermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials.Zoe D Draelos, Emil A Tanghetti, Leon H Kircik, Neal Bhatia, Joshua A Zeichner
The Journal of Dermatological Treatment. 2023-12-01
Press Mentions
Advances in Pediatric Eczema TreatmentJanuary 3rd, 2020
Sol-Gel Technologies Hosting Analyst & Investor DayJuly 25th, 2019
Luma Therapeutics Announces Positive Clinical Data for the Illuvinate System, a New in-Home Treatment for PsoriasisMarch 6th, 2019- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
